scholarly journals An observational study of giant cell interstitial pneumonia and lung fibrosis in hard metal lung disease

BMJ Open ◽  
2014 ◽  
Vol 4 (3) ◽  
pp. e004407 ◽  
Author(s):  
Junichi Tanaka ◽  
Hiroshi Moriyama ◽  
Masaki Terada ◽  
Toshinori Takada ◽  
Eiichi Suzuki ◽  
...  
2012 ◽  
Vol 13 (3) ◽  
pp. 134-136
Author(s):  
Duygu Gurel ◽  
Aydanur Kargi ◽  
Mehtat Unlu ◽  
Eyup Sabri Ucan ◽  
Ahmet Onen

2001 ◽  
Vol 22 (04) ◽  
pp. 435-448 ◽  
Author(s):  
Benoit Nemery ◽  
Erik K. Verbeken ◽  
Maurits Demedts

2016 ◽  
Vol 42 (6) ◽  
pp. 447-452 ◽  
Author(s):  
Rafael Futoshi Mizutani ◽  
◽  
Mário Terra-Filho ◽  
Evelise Lima ◽  
Carolina Salim Gonçalves Freitas ◽  
...  

ABSTRACT Objective: To describe diagnostic and treatment aspects of hard metal lung disease (HMLD) and to review the current literature on the topic. Methods: This was a retrospective study based on the medical records of patients treated at the Occupational Respiratory Diseases Clinic of the Instituto do Coração, in the city of São Paulo, Brazil, between 2010 and 2013. Results: Of 320 patients treated during the study period, 5 (1.56%) were diagnosed with HMLD. All of those 5 patients were male (mean age, 42.0 ± 13.6 years; mean duration of exposure to hard metals, 11.4 ± 8.0 years). Occupational histories were taken, after which the patients underwent clinical evaluation, chest HRCT, pulmonary function tests, bronchoscopy, BAL, and lung biopsy. Restrictive lung disease was found in all subjects. The most common chest HRCT finding was ground glass opacities (in 80%). In 4 patients, BALF revealed multinucleated giant cells. In 3 patients, lung biopsy revealed giant cell interstitial pneumonia. One patient was diagnosed with desquamative interstitial pneumonia associated with cellular bronchiolitis, and another was diagnosed with a hypersensitivity pneumonitis pattern. All patients were withdrawn from exposure and treated with corticosteroid. Clinical improvement occurred in 2 patients, whereas the disease progressed in 3. Conclusions: Although HMLD is a rare entity, it should always be included in the differential diagnosis of respiratory dysfunction in workers with a high occupational risk of exposure to hard metal particles. A relevant history (clinical and occupational) accompanied by chest HRCT and BAL findings suggestive of the disease might be sufficient for the diagnosis.


1989 ◽  
Vol 13 (7) ◽  
pp. 581-587 ◽  
Author(s):  
N. Paul Ohori ◽  
Frank C. Sciurba ◽  
Gregory R. Owens ◽  
Michael J. Hodgson ◽  
Samuel A. Yousem

2016 ◽  
Vol 50 ◽  
pp. 176-182 ◽  
Author(s):  
Andras Khoor ◽  
Anja C. Roden ◽  
Thomas V. Colby ◽  
Victor L. Roggli ◽  
Mohamed Elrefaei ◽  
...  

2016 ◽  
Vol 48 (6) ◽  
pp. 1710-1720 ◽  
Author(s):  
Chad A. Newton ◽  
Kiran Batra ◽  
Jose Torrealba ◽  
Julia Kozlitina ◽  
Craig S. Glazer ◽  
...  

Heterozygous mutations in four telomere-related genes have been linked to pulmonary fibrosis, but little is known about similarities or differences of affected individuals.115 patients with mutations in telomerase reverse transcriptase (TERT) (n=75), telomerase RNA component (TERC) (n=7), regulator of telomere elongation helicase 1 (RTEL1) (n=14) and poly(A)-specific ribonuclease (PARN) (n=19) were identified and clinical data were analysed.Approximately one-half (46%) had a multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF); others had unclassifiable lung fibrosis (20%), chronic hypersensitivity pneumonitis (12%), pleuroparenchymal fibroelastosis (10%), interstitial pneumonia with autoimmune features (7%), an idiopathic interstitial pneumonia (4%) and connective tissue disease-related interstitial fibrosis (3%). Discordant interstitial lung disease diagnoses were found in affected individuals from 80% of families. Patients with TERC mutations were diagnosed at an earlier age than those with PARN mutations (51±11 years versus 64±8 years; p=0.03) and had a higher incidence of haematological comorbidities. The mean rate of forced vital capacity decline was 300 mL·year−1 and the median time to death or transplant was 2.87 years. There was no significant difference in time to death or transplant for patients across gene mutation groups or for patients with a diagnosis of IPF versus a non-IPF diagnosis.Genetic mutations in telomere related genes lead to a variety of interstitial lung disease (ILD) diagnoses that are universally progressive.


2002 ◽  
Vol 52 (4) ◽  
pp. 419
Author(s):  
Ji Hyun Hong ◽  
Jae Myung Lee ◽  
Min Jong Kang ◽  
Dong Gyu Kim ◽  
Ki Suck Jung ◽  
...  

Respiration ◽  
2006 ◽  
Vol 73 (6) ◽  
pp. 833-835 ◽  
Author(s):  
Balakrishnan Menon ◽  
Amit Sharma ◽  
Jai Kripalani ◽  
Sudhir Jain

Sign in / Sign up

Export Citation Format

Share Document